The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …

RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …

Conspectus Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a
homogeneous lipid core. These vesicles are widely used in small-molecule drug and …

Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …

mRNA vaccines have been demonstrated as a powerful alternative to traditional
conventional vaccines because of their high potency, safety and efficacy, capacity for rapid …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus
disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome …

Abstract mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-
19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology …